Hemogenyx Pharmaceuticals Financials

HEMO Stock   343.40  20.90  6.48%   
We strongly advise to harness Hemogenyx Pharmaceuticals fundamental analysis to see if markets are presently undervaluing or overvaluing the company. Simply put, you can make use of it to find out if Hemogenyx Pharmaceuticals is indeed mispriced or if you can make any profits on it by purchasing it and then waiting for the market to recognize its mistake and reprise the security. We are able to interpolate and collect twenty-one available reported financial drivers for Hemogenyx Pharmaceuticals, which can be compared to its competitors. The stock experiences a very speculative upward sentiment. Check odds of Hemogenyx Pharmaceuticals to be traded at 429.25 in 90 days. Key indicators impacting Hemogenyx Pharmaceuticals' financial strength include:
Return On Equity
(1.56)
  
Understanding current and past Hemogenyx Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Hemogenyx Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Hemogenyx Pharmaceuticals' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Hemogenyx Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Hemogenyx Pharmaceuticals PLC. Check Hemogenyx Pharmaceuticals' Beneish M Score to see the likelihood of Hemogenyx Pharmaceuticals' management manipulating its earnings.

Hemogenyx Pharmaceuticals Stock Summary

Hemogenyx Pharmaceuticals competes with Toyota, SoftBank Group, OTP Bank, Public Service, and Baker Hughes. Hemogenyx Pharmaceuticals is entity of United Kingdom. It is traded as Stock on LSE exchange.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUK Stock View All
ExchangeLondon Exchange
ISINGB00BYX3WZ24
Business Address60 Gracechurch Street,
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitehemogenyx.com
Phone44 79 0917 7311
You should never invest in Hemogenyx Pharmaceuticals without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Hemogenyx Stock, because this is throwing your money away. Analyzing the key information contained in Hemogenyx Pharmaceuticals' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Hemogenyx Pharmaceuticals Key Financial Ratios

There are many critical financial ratios that Hemogenyx Pharmaceuticals' investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Hemogenyx Pharmaceuticals reports annually and quarterly.

Hemogenyx Pharmaceuticals Key Balance Sheet Accounts

201920202021202220232024 (projected)
Total Assets1.0M2.7M8.5M7.1M6.1M3.5M
Net Debt758.6K(184.2K)(6.8M)890.1K1.7M1.8M
Retained Earnings(6.0M)(8.0M)(13.1M)(17.1M)(23.8M)(22.6M)
Cash498.7K1.8M6.8M2.5M1.2M1.9M
Other Current Assets55.8K105.0K298.2K62.0K922.0K968.1K
Total Current Assets554.5K1.9M7.1M2.6M2.2M2.1M
Common Stock3.6M3.6M4.3M9.8M11.8M12.3M
Other Current Liab80.3K47.5K46.9K51.9K77.3K71.2K
Net Tangible Assets686.4K(608.6K)635.9K7.8M8.9M9.4M
Accounts Payable61.4K113.2K295.8K374.3K301.7K154.9K
Total Liab1.4M1.8M352.8K3.8M3.3M3.5M
Intangible Assets272.8K262.1K255.0K441.5K470.2K356.6K
Net Receivables32.3K56.3K7.5K9.8K5.1K4.9K
Net Invested Capital797.6K2.5M8.2M3.3M2.8M3.4M
Net Working Capital372.9K138.4K6.8M1.8M1.5M2.2M

Hemogenyx Pharmaceuticals Key Income Statement Accounts

201920202021202220232024 (projected)
Interest Expense31.3K33.2K2.6M33.0316.0K365.3K
Operating Income(1.7M)(2.2M)(2.7M)4.0M(6.5M)(6.1M)
Ebit(1.5M)(2.1M)(2.5M)(4.0M)(6.4M)(6.1M)
Ebitda(1.4M)(2.0M)(2.4M)(3.4M)(5.7M)(5.4M)
Income Before Tax(1.5M)(2.1M)(5.1M)(4.0M)(6.7M)(6.4M)
Net Income(1.5M)(2.1M)(7.5M)(4.3M)(6.7M)(6.4M)
Gross Profit(421.8K)(350.7K)(283.6K)(2.6M)(645.7K)(678.0K)
Income Tax Expense(35K)20.4K2.4M361.2K(5.8K)(5.5K)
Interest Income14.2K3.4K18.0K10.6K85.3K89.6K
Research Development21.2583.6637.58402.9490.6K95.2K
Cost Of Revenue421.8K350.7K283.6K2.6M645.7K653.2K
Net Interest Income(17.1K)(29.9K)(2.6M)10.6K(230.6K)(242.2K)

Hemogenyx Pharmaceuticals Key Cash Accounts

201920202021202220232024 (projected)
Change In Cash(1.3M)1.3M5.0M(4.3M)(1.3M)(1.2M)
Free Cash Flow(1.2M)(2.0M)(3.4M)(3.3M)(6.2M)(5.9M)
Capital Expenditures11.9K173.0K818.0K428.9K117.3K180.2K
Net Income(1.5M)(2.1M)(5.1M)(4.0M)(6.7M)(6.4M)
End Period Cash Flow498.7K1.8M6.8M2.5M1.2M1.9M
Other Non Cash Items17.1K30.0K2.1M621.0K772.8K663.1K
Investments2.3K(169.7K)(939.0K)(420.3K)(31.9K)(33.5K)
Net Borrowings1.2M(39.4K)420.5K(3.2M)(2.9M)(2.8M)
Depreciation94.7K106.8K126.3K195.2K645.7K678.0K
Change To Netincome157.9K233.6K2.2M630.9K725.5K845.2K

Hemogenyx Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Hemogenyx Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Hemogenyx Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Hemogenyx Pharmaceuticals competition to find correlations between indicators driving Hemogenyx Pharmaceuticals's intrinsic value. More Info.
Hemogenyx Pharmaceuticals PLC is rated # 4 in return on equity category among its peers. It is one of the top stocks in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Hemogenyx Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Hemogenyx Pharmaceuticals Systematic Risk

Hemogenyx Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Hemogenyx Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Hemogenyx Pharmaceuticals correlated with the market. If Beta is less than 0 Hemogenyx Pharmaceuticals generally moves in the opposite direction as compared to the market. If Hemogenyx Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Hemogenyx Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Hemogenyx Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Hemogenyx Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.

Hemogenyx Pharmaceuticals PLC Total Assets Over Time

Hemogenyx Pharmaceuticals December 22, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Hemogenyx Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Hemogenyx Pharmaceuticals PLC. We use our internally-developed statistical techniques to arrive at the intrinsic value of Hemogenyx Pharmaceuticals PLC based on widely used predictive technical indicators. In general, we focus on analyzing Hemogenyx Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Hemogenyx Pharmaceuticals's daily price indicators and compare them against related drivers.

Additional Tools for Hemogenyx Stock Analysis

When running Hemogenyx Pharmaceuticals' price analysis, check to measure Hemogenyx Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hemogenyx Pharmaceuticals is operating at the current time. Most of Hemogenyx Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Hemogenyx Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hemogenyx Pharmaceuticals' price. Additionally, you may evaluate how the addition of Hemogenyx Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.